Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans
top of page
bottom of page
Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans
Comentários